Compare AbCellera Biologics Inc (ABCL) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Vanguard Information Technology Index Fund ETF trades at $115.24. Which is the better fit depends on your goals.
| ABCL | VGT | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $125.77 |
52-Week Low | $2.78 | $83.59 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
The Vanguard Information Technology ETF (VGT) trades at $116.37, up 1.51% on the day, with technical indicators showing a mixed but slightly bullish bias. The fund recently executed an 8-for-1 stock split and maintains a low 0.09% expense ratio, positioning it as a cost-efficient vehicle for broad tech exposure. Financial media sentiment is generally positive, highlighting VGT's strong long-term track record and diversification benefits compared to more concentrated tech ETFs.
The outlook for VGT is tied to the broader technology sector's performance, particularly hyperscaler capital expenditure and semiconductor cycles. Key opportunities include exposure to AI-driven growth through a diversified portfolio. Primary risks involve sector concentration, market volatility, and potential valuation pressures if tech earnings growth decelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
